Clinical effect of ulinastatin in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a Meta-analysis

Li Lu; Wei HongCheng; Feng ShuFen

doi:10.3969/j.issn.1001-5256.2017.01.024

Issue 1

Jan. 2017

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(1): 110-115

PDF( 1779 KB)

Clinical effect of ulinastatin in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2017.01.024

Department of Gastroenterology, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China

Published Date: 2017-01-20

Abstract

Abstract

Objective To investigate the clinical effect of ulinastatin in preventing pancreatitis after endoscopic retrograde cholangiopancreatography( ERCP). Methods The Cochrane Library,Pub Med,EMBASE,CNKI,VIP,and Wanfang Data were searched for randomized controlled trials( RCTs) on ulinastatin for the prevention of post- ERCP pancreatitis published from 1970 to June 2016. Two researchers selected RCTs,extracted data,and evaluated methodological quality independently,and Rev Man 5. 3 software was used for the meta- analysis. The chi- square test was used for the heterogeneity analysis of RCTs included,and the funnel plots were used to evaluate publication bias. Results A total of six RCTs with 923 patients were included in this analysis. Compared with the placebo,ulinastatin had significantly better effects in preventing post- ERCP pancreatitis( OR = 0. 26,95% CI: 0. 13- 0. 53,P = 0. 000 2),hyperamylasemia( OR = 0. 47,95% CI: 0. 33- 0. 67,P < 0. 001),and abdominal pain( OR = 0. 56,95% CI: 0. 34- 0. 91,P = 0. 020). Compared with gabexate,ulinastatin had similar effects in preventing post- ERCP pancreatitis,hyperamylasemia,and abdominal pain( P = 0. 52,0. 13,and 0. 79);low- dose ulinastatin also had similar effects as gabexate in preventing post- ERCP pancreatitis and hyperamylasemia( P = 0. 49 and0. 25). The funnel plots based on the effect of ulinastatin in preventing post- ERCP pancreatitis were slightly asymmetric,which suggested the presence of publication bias. Conclusion Ulinastatin( ≥15 × 104U) can effectively prevent post- ERCP pancreatitis,hyperlipidemia,and abdominal pain in the general population and it is recommended to start using this drug before surgery.
- pancreatitis,
- cholangiopancreatography,
- endoscopic retrograde,
- postoperative complications,
- ulinastatin

FullText(HTML)

References(23)

References

[1]MIAO L,WANG F.Recent progress in ERCP for biliary and pancreatic diseases[J].J Clin Hepatol,2014,30(12):1259-1265.(in Chinese)缪林,王飞.经内镜逆行胰胆管造影在胆胰疾病中的应用[J].临床肝胆病杂志,2014,30(12):1259-1265.

[2]PARSI MA.NSAIDs for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography:ready for prime time?[J].World J Gastroenterol,2012,18(30):3936-3937.

[3]YOO YW,CHA SW,KIM A,et al.The use of gabexate mesylate and ulinastatin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis[J].Gut Liver,2012,6(2):256-261.

[4]LIU C,ZHANG L.Somatostatin and its analogues combined with proton pump inhibitor in prevention of post-ERCP pancreatitis:a meta-analysis[J].J Clin Hepatol,2015,31(9):1464-1468.(in Chinese)刘超,张磊.生长抑素及其类似物联合质子泵抑制剂预防经内镜逆行胰胆管造影术后胰腺炎的Meta分析[J].临床肝胆病杂志,2015,31(9):1464-1468.

[5]ZHANG FB,ZHU B,LIU W,et al.The clinical effect of octreotide combined with indomethacin on pancreatitis and hyperamylasemia after ERCP[J].Clin J Med Offic,2015,43(7):752-753,755.(in Chinese)章福彬,朱斌,刘卫,等.奥曲肽联合吲哚美辛栓剂预防ERCP术后胰腺炎和高淀粉酶血症的临床研究[J].临床军医杂志,2015,43(7):752-753,755.

[6]CHEN CC,WANG SS,LEE FY.Action of antiproteases on the inflammatory response in acute pancreatitis[J].JOP,2007,8(Suppl4):488-494.

[7] COTTON PB,LEHMAN G,VENNES J,et al.Endoscopic sphincterotomy complications and their management:an attempt at consensus[J].Gastrointest Endosc,1991,37(3):383-393.

[8]TSUJINO T,KOMATSU Y,ISAYAMA H,et al.Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography:a randomized,controlled trial[J].Clin Gastroenterol Hepatol,2005,3(4):376-383.

[9]PARK JY,JEON TJ,HWANG MW,et al.Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications:a prospective,randomized trial[J].Pancreatology,2014,14(4):263-267.

[10]CHEN X,XIA CM,YAN HF,et al.Clinical effect of ulinastatin versus octreotide in prevention and treatment of pancreatitis after endoscopic retrograde cholangiopancreatography[J].Chin J Rural Med Pharm,2015,22(17):20-21.(in Chinese)陈霞,夏晨梅,颜海帆,等.乌司他丁与奥曲肽预防治疗性内镜逆行胰胆管造影术后胰腺炎效果比较[J].中国乡村医药,2015,22(17):20-21.

[11]XIONG W,YANG Y,DONG K,et al.Clinical investigation of ulinastatin in preventing and treating hyperamylasemia and acute pancreatitis following endoscopic retrograde cholangio pancreatography[J].Drug Eval,2013,10(2):40-42.(in Chinese)熊伟,杨勇,董科,等.乌司他丁预防ERCP术后高淀粉酶血症及急性胰腺炎的临床研究[J].药品评价,2013,10(2):40-42.

[12]FUJISHIRO H,ADACHI K,IMAOKA T,et al.Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study[J].J Gastroenterol Hepatol,2006,21(6):1065-1069.

[13]UEKI T,OTANI K,KAWAMOTO K,et al.Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis:a prospective,randomized trial[J].J Gastroenterol,2007,42(2):161-167.

[14]DUMONCEAU JM,ANDRIULLI A,DEVIERE J,et al.European Society of Gastrointestinal Endoscopy(ESGE)Guideline:prophylaxis of post-ERCP pancreatitis[J].Endoscopy,2010,42(6):503-515.

[15]TESTONI PA.Preventing post-ERCP pancreatitis:where are we?[J].JOP,2003,4(1):22-32.

[16]GRANGER J,REMICK D.Acute pancreatitis:models,markers,and mediators[J].Shock,2005,24(Suppl 1):45-51.

[17]CAVALLINI G,TITTOBELLO A,FRULLONI L,et al.Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography.Gabexate in digestive endoscopy—Italian Group[J].N Engl J Med,1996,335(13):919-923.

[18]ANDRIULLI A,CLEMENTE R,SOLMI L,et al.Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis:a multicenter,placebo-controlled,randomized clinical trial[J].Gastrointest Endosc,2002,56(4):488-495.

[19]MASCI E,CAVALLINI G,MARIANI A,et al.Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis[J].Am J Gastroenterol,2003,98(10):2182-2186.

[20]OHNISHI H,KOSUZUME H,ASHIDA Y,et al.Therapeutic effects of human urinary trypsin inhibitor on acute experimental pancreatitis[J].Nihon Yakurigaku Zasshi,1983,81(3):235-244.

[21]TSUJINO T,KAWABE T,OMATA M.Antiproteases in preventing post-ERCP acute pancreatitis[J].JOP,2007,8(Suppl 4):509-517.

[22]KUBILIUN NM,ADAMS MA,AKSHINTALA VS,et al.Evaluation of pharmacologic prevention of pancreatitis after endoscopic retrograde cholangiopancreatography:a systematic review[J].Clin Gastroenterol Hepatol,2015,13(7):1231-1239.

[23]YOO JW,RYU JK,LEE SH,et al.Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients:a prospective,randomized,placebocontrolled trial[J].Pancreas,2008,37(4):366-370.

Relative Articles

[1]	Wenhui WANG, Xuhua DUAN, Hao LI, Shuguang JU, Manzhou WANG, Jianzhuang REN, Xinwei HAN. A cost-effect analysis of transarterial chemoembolization with CalliSpheres beads loaded with arsenic trioxide versus arsenic trioxide iodized oil emulsion in treatment of unresectable liver cancer[J]. Journal of Clinical Hepatology, 2021, 37(9): 2125-2129. doi: 10.3969/j.issn.1001-5256.2021.09.024
[2]	Du YiChao, Zhang Hao, Zhong FuRui, Cheng HuanLi, Lai Li, Qian BaoLin, Tan Peng, Xia XianMing, Fu WenGuang. Protective effect of pinocembrin in a mouse model of liver injury induced by acetaminophen[J]. Journal of Clinical Hepatology, 2020, 36(3): 608-611. doi: 10.3969/j.issn.1001-5256.2020.03.027
[3]	Ha FuShuang, Han Tao, Liang Ning, Nie XinHua, Zhu ZhengYan. Effect of recombinant human granulocyte colony-stimulating factor on rats with acute liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1565-1569. doi: 10.3969/j.issn.1001-5256.2019.07.028
[4]	Li ShanShan, Zhang Ke, Cheng ShuJie, Yang JiHong, Gao Feng, Li JingHua. Current status and future perspectives of the application of medical 3D visualization technology in accurate surgery of liver tumors[J]. Journal of Clinical Hepatology, 2019, 35(5): 1114-1117. doi: 10.3969/j.issn.1001-5256.2019.05.042
[5]	Zhang YongChao, Bi YanZhen, Fang Xiao, Wang QuanYi, Wang QuanQuan, Tang HuiXin, Kong LingBin, Chen Yu, Duan ZhongPing, Shu ZhenFeng, Hong Feng. Protective effect of probiotics in rats with acute-on-chronic liver failure and related mechanism[J]. Journal of Clinical Hepatology, 2019, 35(7): 1570-1575. doi: 10.3969/j.issn.1001-5256.2019.07.029
[6]	Wang Hao, He Cheng, Chen Hao, Ou YangZhongMin, Liu ZhiQiang. Value of Gd-EOB-DTPA-enhanced MRI in the assessment of liver function in dogs with acute liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1576-1581. doi: 10.3969/j.issn.1001-5256.2019.07.030
[7]	Zhou QiFeng, Zhang LingQiang, Liao MengJiao, Pang MingQuan, Li MengXuan, Ren Li, Fan HaiNing. Establishment of a subcutaneous xenograft tumor model of alveolar echinococcosis in nude mice[J]. Journal of Clinical Hepatology, 2018, 34(3): 588-590. doi: 10.3969/j.issn.1001-5256.2018.03.028
[8]	Ji JunSong, Chen Ting, Wang Hui, Wang ChenYi, Zhu XinYing, Yin Hao, Fu ZhiRen. Effect of arsenic trioxide chemotherapy on survival time in liver cancer patients undergoing liver transplantation[J]. Journal of Clinical Hepatology, 2017, 33(9): 1745-1748. doi: 10.3969/j.issn.1001-5256.2017.09.023
[9]	Li Dong, Lu ZhongHua, Gan JianHe. Establishment of a rat model of early-stage liver failure and Th17/Treg imbalance[J]. Journal of Clinical Hepatology, 2016, 32(5): 928-932. doi: 10.3969/j.issn.1001-5256.2016.05.025
[10]	Chen Jing, Liu XiaoYan, Yang HaoZhen, Huang Kun, Hu JinHua, Xin ShaoJie. Study on p-p38 expression and its significance in liver tissues of mice with acute liver failure and patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2015, 31(4): 556-559. doi: 10.3969/j.issn.1001-5256.2015.04.019
[11]	Pang GuoJin, Chen ShuangJun, Zhao WeiHua, Liu TianHui, Wang Ping, You Hong, Cong Min. Dynamic change of hepcidin in liver fibrosis induced by CCl4 among mice[J]. Journal of Clinical Hepatology, 2015, 31(3): 418-423. doi: 10.3969/j.issn.1001-5256.2015.03.025
[12]	Gao ChengGuang, Chen RiXia. Clinical research on treatment of advanced primary liver cancer with combination of thymosin α1 and arsenic trioxide[J]. Journal of Clinical Hepatology, 2015, 31(4): 564-568. doi: 10.3969/j.issn.1001-5256.2015.04.021
[13]	Huang HaiYan, Xin YongNing, Jiang Man, Jin WenWen, Jiang XiangJun, Xuan ShiYing. Research advances in animal models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2014, 30(9): 948-953. doi: 10.3969/j.issn.1001-5256.2014.09.028
[14]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[15]	Jiang Han, Wang XueFeng, Wang ZiHao, Xu Bin, Shi WeiBin. The establishment of rabbit VX2 hepatic tumor model and the application of nano-scale microbubble contrast agent in the diagnosis of this model[J]. Journal of Clinical Hepatology, 2011, 27(7): 746-748.
[16]	Sun LinLin, Shi Jun, Hao JingHua, Ren WanHua, Yan ChunYing, Zhang Jie, Lin XiaoYan, Cui Bin. Effect of high-fat diet on establishment of a rat non-alcoholic steatohepatitis/liver fibrosis model[J]. Journal of Clinical Hepatology, 2011, 27(3): 254-257+272.
[17]	Ye LiHong, Wang ChongKui, Tian YueYang, Xu Yi, Zheng HaoJie, Shao ShiXiang, Dai ErHei. Effect of Ruangan Huajian granule on hepatic expression of PDGF - B in C57 mice with experimental hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1047-1050.
[18]	Song Yu, Yu Zheng, Fan YanHua, Yao ShuKun, Wang TaiLing. A rat model of hepatic veno-occlusive disease induced by the Gynura root water decoction[J]. Journal of Clinical Hepatology, 2011, 27(8): 860-864.
[19]	Lou GuoHua, Liu YanNing, Yin ChunBen, Chen Feng, Jia ZhanSheng, Chen Zhi. Preliminary study of HCV mouse model induced by infectious HCV 2a plasmid[J]. Journal of Clinical Hepatology, 2011, 27(1): 72-75.

Supplements(0)

Cited By

Cited by

Periodical cited type(10)

1.	杨晓曼. γ-谷氨酰转移酶/血小板在乙肝肝硬化失代偿期患者中的表达及临床意义. 河南医学研究. 2024(08): 1407-1410 .
2.	刘爱华，符建，陈小红. 瞬时超声弹性成像联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化价值研究. 实用肝脏病杂志. 2023(05): 634-637 .
3.	肖少伟，杜亚哲. γ-谷氨酰转移酶/胆碱酯酶比值与γ-谷氨酰转移酶/血小板比值对慢性乙型肝炎患者肝纤维化程度的预测效能. 实用医技杂志. 2023(11): 812-815 .
4.	张玉婷，施欢，李虤，沈波. FibroTouch联合GGT/PLT比值对诊断乙型肝炎肝纤维化的临床价值. 江西医药. 2022(02): 206-209+216 .
5.	桑阿利. APRI、Fib-4和Fibroscan联合诊断慢性乙型肝炎肝纤维化程度的价值. 甘肃医药. 2022(10): 896-898 .
6.	王晔恺，于倩，姚燕珍，罗雯斌，洪开听，鲍舟君. 对数几率回归模型构建联合预测因子对慢性乙型肝炎患者早期肝硬化诊断的临床应用. 中国卫生检验杂志. 2021(01): 90-93+97 .
7.	陈兴，梁小桃. 肝瞬时弹性成像与天冬氨酸转氨酶/血小板指数在慢性乙型肝炎合并脂肪肝患者肝纤维化诊断中的应用价值. 中国当代医药. 2021(11): 60-62 .
8.	黄腊平，陈焰. 基于Fibroscan技术的柴胡疏肝散对非酒精性脂肪肝患者临床疗效分析. 清远职业技术学院学报. 2020(02): 35-38 .
9.	栗红江，何久胜，胡素玲，何福亮，田彦卿，刘震霞. 声辐射力脉冲成像技术、瞬时弹性成像技术及天冬氨酸氨基转移酶与血小板比率指数联合检测乙型肝炎肝纤维化程度临床效能. 临床军医杂志. 2020(09): 1090-1091+1094 .
10.	熊静，林登娜，翁伟镇，陈俊峰，曹会娟，张绍全，张静，高隽，林炳亮. FIB-4联合血清PCⅢ、ⅣC评估乙型肝炎病毒相关肝纤维化. 国际病毒学杂志. 2020(05): 403-406 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2278) PDF downloads(406)

Clinical effect of ulinastatin in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2017.01.024